{
  "frames":[
    {
      "text":"Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes.    Insulin-like growth factor 1 (IGF-1) has poor anabolic efficacy in cartilage in osteoarthritis (OA), partly because of its sequestration by abnormally high levels of extracellular IGF-binding proteins (IGFBPs). We studied the effect of NBI-31772, a small molecule that inhibits the binding of IGF-1 to IGFBPs, on the restoration of proteoglycan synthesis by human OA chondrocytes. IGFBPs secreted by human OA cartilage or cultured chondrocytes were analyzed by western ligand blot. The ability of NBI-31772 to displace IGF-1 from IGFBPs was measured by radiobinding assay. Anabolic responses in primary cultured chondrocytes were assessed by measuring the synthesis of proteoglycans in cetylpyridinium-chloride-precipitable fractions of cell-associated and secreted  35 S-labeled macromolecules. The penetration of NBI-31772 into cartilage was measured by its ability to displace  125 I-labeled IGF-1 from cartilage IGFBPs. We found that IGFBP-3 was the major IGFBP secreted by OA cartilage explants and cultured chondrocytes. NBI-31772 inhibited the binding of  125 I-labeled IGF-1 to IGFBP-3 at nanomolar concentrations. It antagonized the inhibitory effect of IGFBP-3 on IGF-1-dependent proteoglycan synthesis by rabbit chondrocytes. The addition of NBI-31772 to human OA chondrocytes resulted in the restoration or potentiation of IGF-1-dependent proteoglycan synthesis, depending on the IGF-1 concentrations. However, NBI-31772 did not penetrate into cartilage explants. This study shows that a new pharmacological approach that uses a small molecule inhibiting IGF-1/IGFBP interaction could restore or potentiate proteoglycan synthesis in OA chondrocytes, thereby opening exciting possibilities for the treatment of OA and, potentially, of other joint-related diseases.      Introduction.  Insulin-like growth factor 1 (IGF-1) was originally discovered in 1957 by Salmon and Daughaday as a potent growth-hormone-dependent serum factor able to stimulate sulfate incorporation by cartilage in vitro [XREF_BIBR]. During postnatal, childhood, and pubertal life, IGF-1 stimulates the linear growth of bones by increasing the proliferation of epiphyseal chondrocytes and remodeling processes within the growth plate cartilage [XREF_BIBR,XREF_BIBR]. During adulthood, IGF-1 plays a crucial role in the maintenance of homeostasis in articular cartilage, by stimulating the production of matrix proteins by chondrocytes [XREF_BIBR-XREF_BIBR], counteracting their degradation [XREF_BIBR-XREF_BIBR], and preventing cell death [XREF_BIBR,XREF_BIBR]. IGF-1 displays its biological effects in cartilage through the IGF-1 tyrosine kinase receptor [XREF_BIBR], structurally related to the heterotetrameric insulin receptor [XREF_BIBR]. The accessibility of IGF-1 to its receptor is regulated by extracellular IGF-binding proteins (IGFBPs), secreted by chondrocytes but also by the other joint tissues. Although the secretion of IGFBPs by chondrocytes is constitutive, it is also stimulated by IGF-1 itself. This mechanism regulates the amount of the free, bioactive form of IGF-1 [XREF_BIBR,XREF_BIBR]. In case of need, IGF-1 can be released from IGFBPs. The proteolytic cleavage of IGFBPs by various proteases dramatically decreases their affinity for IGF-1, thereby increasing its bioavailability [XREF_BIBR].  The action of IGF-1 in cartilage is altered during ageing and in various pathologies such as osteoarthritis (OA), leading to a decrease of anabolism and a detrimental increase in catabolic events [XREF_BIBR]. Despite the increased degradation of cartilage in OA, the expression of IGF-1 mRNA is up-regulated in lesions of OA human cartilage [XREF_BIBR-XREF_BIBR], and IGF-1 protein levels rise in the synovial fluid of OA patients compared to healthy subjects [XREF_BIBR-XREF_BIBR]. In dogs, IGF-1 levels in a knee joint that had undergone cruciate ligament rupture were fourfold higher than in the contralateral, unaffected joint [XREF_BIBR]. This increased production of IGF-1 in OA reflected an attempt of cartilage to restore homeostasis, but it remained inefficacious. IGF-1 receptors were present and functional in chondrocytes from OA cartilage and thus were not responsible for the inability of IGF-1 to trigger anabolic events [XREF_BIBR,XREF_BIBR,XREF_BIBR].  IGFBPs are key players in the failure of cartilage to readjust to homeostasis during OA. Of the six known IGFBPs, IGFBP-2, -3, and -4 are known to be secreted by articular cartilage or chondrocytes [XREF_BIBR-XREF_BIBR], with IGFBP-3 being the predominant one [XREF_BIBR]. The expression of IGFBP-3 was 24 times as high in human OA chondrocytes as in normal chondrocytes [XREF_BIBR], and the amount of IGFBP-3 synthesized by OA cartilage was three times that in normal cartilage [XREF_BIBR]. Similarly, the amount of IGFBP-3 in OA was three times that seen in healthy cartilage, and was positively correlated with the severity of the disease [XREF_BIBR]. The molar concentration of IGFBP-3 in the synovial fluid of OA patients was higher than that of IGF-1, leading to a molar ratio of free to bound IGF-1 of less than 1 [XREF_BIBR,XREF_BIBR]. In such conditions, no more IGF-1 should be able to reach its receptors on cartilage. To demonstrate the involvement of IGFBPs in IGF-1 bioactivity in vitro, Sunic and co-workers showed that des (1-3) IGF-1, a mutant of IGF-1 lacking the N-terminal tripeptide and with decreased affinity for IGFBPs, stimulated the production of proteoglycans by cultured chondrocytes to a higher extent than did IGF-1 [XREF_BIBR]. Additionally, anabolic responses of chondrocytes to IGF-1 were dependent on the level of secreted IGFBPs, and the addition of IGFBP-3 blocked the effects of IGF-1 [XREF_BIBR].  According to the growing evidence that IGFBPs (and especially IGFBP-3) are involved in the decline of the synthesizing responses of OA cartilage, we hypothesized that these proteins could be pharmacological targets for the treatment of OA. In this study, a nonpeptide small molecule previously described as a potent inhibitor of interaction between IGF and IGFBP [XREF_BIBR] was used as a potential tool to restore the anabolic response of OA chondrocytes to IGF-1.    Results.    Implication of IGFBPs in the loss of anabolic response in OA human chondrocytes.  The ability of IGF-1 to stimulate proteoglycan synthesis in human OA chondrocytes was compared with that of R 3  IGF-1, an IGF-1 analog with a greatly reduced affinity for IGFBPs                . A 48-hour stimulation time with 2.7 nM IGF-1 was ineffective in promoting proteoglycan synthesis by chondrocytes. By contrast, 2.7 nM R 3  IGF-1 significantly stimulated total proteoglycan synthesis, by 45% over that by unstimulated cells. Since IGF-1 and R 3  IGF-1 have similar affinities for the IGF-1 receptor, the anabolic effect of IGF peptides depended on the presence of IGFBPs in the extracellular medium.    Identification of IGFBPs secreted by human OA cartilage and chondrocytes.  To analyze IGFBPs secreted by chondrocytes, aliquots of the secretion medium of primary cultured chondrocytes or cartilage explants were subjected to SDS-PAGE followed by western ligand blotting                . The identity of secreted IGFBPs was determined by running rhIGFBP-1, -2, -3, -4, -5, and -6 in neighbouring wells during electrophoresis. Primary cultured chondrocytes secreted IGFBP-3 as the majority IGFBP form (appearing as a characteristic doublet at 39-42 kDa), and IGFBP-4 was also identified in all specimens consistently, although more faintly. IGFBP-2 was also found in some specimens. By contrast, IGFBP-3 was the only IGFBP secreted by OA cartilage explants from various specimens.    Effect of NBI-31772 on proteoglycan synthesis by rabbit articular chondrocytes.  Since they respond normally to IGF-1, primary cultured rabbit articular chondrocytes were chosen to study the effect of exogenous IGFBP-3 and NBI-31772 on IGF-1 stimulated proteoglycan synthesis                . IGF-1 (1.3 nM) alone stimulated total proteoglycan synthesis by a factor of 3.2                . The addition of a fourfold molar excess of IGFBP-3 completely abolished the anabolic effect of IGF-1, and a slight deleterious effect was even noticed, with proteoglycan synthesis being 18% less than the control value. Further addition of NBI-31772 antagonized the neutralizing effect of IGFBP-3 on the anabolic effect of IGF-1. NBI-31772 (1 muM) increased proteoglycan synthesis over that measured in the presence of IGF-1 plus IGFBP-3 by 28% (P < 0.05) and this increase reached 210% with 10 muM of NBI-31772 (P < 0.001), corresponding to 154% over the basal control value. NBI-31772 by itself had no effect on proteoglycan synthesis. NBI-31772 at 10 muM significantly stimulated the percentage of cell-associated proteoglycans in the presence of IGF-1 plus IGFBP-3, with a value of 40.3% compared to a control value of 31.3% (P < 0.001)                . NBI-31772 alone did not significantly affect the ratio of cell-associated proteoglycans.    Effect of NBI-31772 on proteoglycan synthesis by human OA chondrocytes.  Depending on the concentration used, IGF-1 has no or little effect on proteoglycan synthesis by human OA chondrocytes, whereas R 3  IGF-1 displays higher activity. It therefore seems that endogenous IGFBPs are the main determinants of chondrocyte insensitivity to the action of IGF-1. To further test this hypothesis, we incubated chondrocytes for 24 hours with IGF-1 and then added NBI-31772 to the medium and incubated them for 24 more hours. We hypothesized that, once captured by IGFBPs secreted in the extracellular medium, IGF-1 should be released by addition of the small inhibitor compound and be able to interact again with its receptor.  IGF-1 at 3.3 nM had no significant anabolic effect (an increase of 7.8%; not statistically significant) in comparison with the basal control, but the addition of NBI-31772 at 10 muM stimulated proteoglycan synthesis by 47% over IGF-1 alone (P < 0.001), or 58% over the basal control                . A stimulating concentration of IGF-1 (13.3 nM) led to a 52.4% increase in proteoglycan synthesis over the basal control, and further addition of NBI-31772 at 10 muM brought this increase to 104.2% (34% more than with IGF-1 alone; P < 0.001)                . NBI-31772 alone (added to cells that did not receive IGF-1) had no effect on proteoglycan synthesis. These results suggest that NBI-31772 either restored or augmented IGF-1-dependent anabolism in human OA chondrocytes by disrupting the interaction of the growth factor with its endogenous IGFBPs. As also observed in rabbit articular chondrocytes, NBI-31772 at 10 muM stimulated the percentage of cell-associated proteoglycans compared with IGF-1 used at 3.3 nM or 13.3 nM, with values significantly increasing from 13.5% to 15.9% of total proteoglycans in the former case (P < 0.05), and from 13.0% to 16.0% (P < 0.001) in the latter case                             .  In further experiments, the stimulating effect of NBI-31772 was tested in the presence of R 3  IGF-1 by comparison with IGF-1. Since R 3  IGF-1 does not bind to IGFBPs, we hypothesized that NBI-31772 should not affect proteoglycan synthesis induced by this mutant IGF-1. As expected, NBI-31772 stimulated IGF-1-dependent proteoglycan synthesis in a dose-dependent manner                , but R 3  IGF-1 activity, which by itself was highly enhanced compared with IGF-1, remained unaffected by NBI-31772                . This experiment definitely ruled out the possibility that NBI-31772 may act independently of its ability to inhibit the interaction between IGF-1 and IGFBP. However, the percentage of cell-associated proteoglycans was significantly increased from 13.6% to 16.5% (P < 0.001) when 10 muM NBI-31772 was added to the medium containing R 3  IGF-1                , showing that the effect of NBI-31772 on proteoglycan redistribution depended on cell responses to IGF-1 peptides, rather than to their ability to bind to IGFBPs. NBI-31772 alone did not affect the percentage of cell-associated proteoglycans (not shown).    Effect of NBI-31772 on  125 I-labeled IGF-1 binding to human OA chondrocytes.  To ensure that NBI-31772 did not affect the binding of IGF-1 to its receptors, it was used as a potential competitor in a cell-binding assay on human OA chondrocytes                .  125 I-labeled IGF-1 bound specifically to confluent chondrocytes, since 84% of the radioactivity could be released by the addition of excess unlabeled IGF-1. When added at the highest dose used in biological assays (10 muM), NBI-31772 did not displace specific  125 I-labeled IGF-1 binding from the cell surface.    Competition assay of NBI-31772 with  125 I-labeled IGF-1 for binding to cartilage.  This experiment was set up to determine whether NBI-31772 would displace  125 I-labeled IGF-1 from its IGFBPs within cartilage. To ensure maximal homogeneity, 20 explants coming from a restricted area of a single cartilage specimen were selected for each well. Cartilage explants previously incubated with potential competitors or not were further incubated with 20,000 dpm  125 I-labeled IGF-1. The amount of  125 I-labeled IGF-1 remaining in cartilage in the presence of 11.7 nM IGF-1 was 53% of the control value, demonstrating that only 47% of the radiolabeled peptide was bound specifically to proteins within cartilage                . No further displacement was observed with higher IGF-1 concentrations (not shown). About 43% of the cartilage-associated radioactivity was removed with 1.5 M NaCl, showing that nearly half of the  125 I-labeled IGF-1 was bound in a nonspecific manner to cartilage through ionic interactions, possibly to proteoglycans. By contrast with IGF-1, R 3  IGF-1 did not compete with  125 I-labeled IGF-1, demonstrating that IGF-1 was primarily bound to IGFBPs within cartilage. NBI-31772 (10 muM) did not compete with  125 I-labeled IGF-1 binding to cartilage IGFBPs, suggesting that it did not penetrate into cartilage.    Discussion.  The loss of anabolic responses of chondrocytes to IGF-1 is one of the reasons why diseased cartilage cannot counteract the action of catabolic cytokines during OA. The results of the present study show that NBI-31772, a small, nonpeptide compound that binds to endogenous IGFBPs and releases biologically active IGF-1 [XREF_BIBR], can restore proteoglycan synthesis by human OA chondrocytes, therefore opening the possibility of a new field of pharmacological intervention for the treatment of OA and other joint-related diseases.  As previously demonstrated in ovine and bovine chondrocytes [XREF_BIBR], a mutant of IGF-1 with strongly decreased affinity for IGFBPs was able to stimulate the synthesis of proteoglycans by OA chondrocytes to a higher extent than did IGF-1. This simple but convincing experiment was the basis for suspecting the involvement of endogenous IGFBPs in the loss of IGF-1 effects in OA chondrocytes, and it was a prerequisite to justify their targeting. Three forms of IGFBPs were found to be secreted by human OA chondrocytes, the major one being IGFBP-3. OA cartilage explants secreted IGFBP-3 exclusively. In a functional radiobinding assay, NBI-31772 displaced the binding of  125 I-labeled IGF-1 at a molar concentration 20 times that of unlabeled IGF-1. Although the ability of NBI-31772 to displace  125 I-labeled IGF-1 from the other IGFBPs has not been checked in this study, it has been previously shown that it can interact with all six IGFBPs with similar efficacy [XREF_BIBR]. Therefore, it is probable that in the experiments with OA chondrocytes, NBI-31772 also acted by displacing IGF-1 from IGFBP-2 and -4 in addition to IGFBP-3.  In the first set of experiments with rabbit chondrocytes, IGFBP-3 at a concentration four times that of IGF-1 completely abolished the stimulation of proteoglycan synthesis by IGF-1, and NBI-31772 partially restored IGF-1-dependent synthetic activities at 1 muM and almost totally at 10 muM. These concentrations were much higher than those found to displace  125 I-labeled IGF-1 from IGFBP-3 in the radiobinding assay. This discrepancy was also found in a previous study reporting the activity of NBI-31772 on the reversal of IGFBP-3 inhibition of Balb/c3T3 IGF-1-dependent proliferation [XREF_BIBR]. The higher amounts of IGFBP-3 used in the biological assays compared with the radiobinding assay may in part account for this discrepancy. On the other hand, differences may rest on a decreased stability of the chemical compound in a biological environment and/or to its capture or neutralization by chondrocyte-secreted proteins or macromolecules, thus limiting its activity. Similar results were found for human OA chondrocytes, without addition of IGFBP-3. In this cellular model, we asked whether NBI-31772 could displace IGF-1 from endogenous IGFBPs. As also found by others [XREF_BIBR,XREF_BIBR,XREF_BIBR], IGF-1 was either not detectable or poorly detectable in the extracellular medium, reflecting poor ability of chondrocytes to secrete IGF-1. Thus, it was given exogenously. The addition of NBI-31772 was able to activate or increase proteoglycan synthesis, showing that complexes of IGF-1 with IGFBP could be disrupted to release bioactive IGF-1. NBI-31772 also significantly increased the ratio of cell-associated proteoglycans in the presence of IGF-1/IGFBP complexes. When, in these experiments, IGF-1 was replaced by R 3  IGF-1, the stimulating effect of NBI-31772 on proteoglycan synthesis was completely abolished, thus ruling out the possibility that NBI-31772 may act independently of the inhibition of IGF-1-binding to IGFBPs. However, an increase of cell-associated proteoglycans was still observed, showing that this effect of NBI-31772 occurred apart from IGFBPs. Although unexplained, this mechanism may be important in a pathological context, since communication between chondrocytes and the extracellular matrix is disrupted in OA, and an increase of pericellular proteoglycans may help to maintain chondrocytes in a more favorable environment.  Under physiological conditions, IGF-1/IGFBP complexes can be disrupted by various proteases [XREF_BIBR], thereby releasing active IGF-1. In a recent report by Fowlkes and co-workers, matrix metalloproteinase 3 was able to disrupt IGF/IGFBP-3 complexes and to liberate free, intact IGFs able to phosphorylate the IGF-1 receptor and to trigger cell proliferation [XREF_BIBR]. A few different approaches have been used to prevent excessive sequestration of IGF-1 and restore its bioavailabity in pathological conditions. Mutant peptides of IGF-1 still able to bind to IGFBPs but with very weak affinity for the IGF-1 receptor were designed to displace native IGF-1 from endogenous IGFBPs [XREF_BIBR-XREF_BIBR]. Phage-displayed peptide libraries yielded small peptide compounds able to selectively displace IGF-1 from IGFBP-1 or IGFBP-3 [XREF_BIBR,XREF_BIBR]. From the last generation, low-molecular-weight compounds (fluorenylmethoxycarbonyl derivatives) were shown to bind to the IGF-1 binding site on IGFBP-5 [XREF_BIBR], and small isoquinoline compounds were shown to displace IGFs from IGFBPs without selectivity for a particular IGFBP [XREF_BIBR,XREF_BIBR,XREF_BIBR,XREF_BIBR,XREF_BIBR]. These molecules have been proposed as potential drug candidates for the treatment of diabetes [XREF_BIBR,XREF_BIBR], renal disease [XREF_BIBR], or neurodegenerative diseases [XREF_BIBR,XREF_BIBR].  Most of the current pharmacological approaches for the treatment of OA aim to prevent catabolism by blocking actors of the deleterious cascade, while restoration of anabolism or cartilage regeneration still rests on invasive procedures [XREF_BIBR]. In this context, in situ cartilage regeneration by growth-factor therapy, including targeting of cartilage defects with fibrin-(chondrocyte)-IGF-1 composites [XREF_BIBR,XREF_BIBR], or gene therapy with IGF-1 delivered intra-articularly [XREF_BIBR-XREF_BIBR], have been proposed. To be effective, the amount of IGF-1 delivered within the joint in this way should exceed the binding capacity of local IGFBPs. In addition to noninvasive intervention, one of the main advantages of our proposed strategy would be to target directly the actors of cartilage unresponsiveness to IGF-1, and to bypass the capture of exogenous IGF-1 by IGFBPs. Keeping this objective in mind, it is clear that the small compound used in this study, NBI-31772, should be considered only a tool to demonstrate the concept in vitro. Indeed, concentrations of NBI-31772 active in the biological assays were relatively high (1-10 muM) and would be incompatible with in vivo trials. Secondly, NBI-31772 did not penetrate into cartilage. This should not be an exclusion criterion per se, since one may hypothesize that if the compound were capable of reaching the synovial fluid or cartilage surrounding tissues, it might release IGF-1 captured by IGFBPs in these tissues and sustain its action in cartilage. However, the in vivo duration of action of NBI-31772 was short [XREF_BIBR], which implies that in vivo trials to assess the therapeutic relevance of this class of molecule in joint diseases need to be performed with more stable molecules. In view of a therapeutic application, the optimization of small chemical inhibitors of IGF/IGFBP interaction would be preferred over the use of IGF-1 peptide mutants (either binding receptors and triggering biological effects without binding IGFBPs, or, conversely, displacing endogenous IGF-1 from IGFBPs without binding receptors), since the former should be more easily optimizable while the latter should be more susceptible to the attack by proteases. In a clinical context, compounds that selectively target IGFBP-3 would be mandatory if oral availability is preferred, in order to avoid or to limit side effects caused by displacing IGF-1 from its binding proteins in undesirable tissues. This question of selectivity may not be so important in the case of topical delivery, and local treatment should be envisaged instead.    Conclusion.  A small, nonpeptide pharmacological inhibitor of IGF/IGFBP interaction restored or enhanced the IGF-1-dependent proteoglycan synthesis by human osteoarthritic chondrocytes. This finding offers a rationale for pharmacological intervention in the treatment of cartilage repair in osteoarthritis and potentially of other joint-related diseases and shows that IGFBPs are pertinent target candidates for this purpose.    Competing interests.  None declared.    Abbreviations.  BSA = bovine serum albumin; DPBS = Dulbecco's phosphate buffered saline without calcium and magnesium; dpm = disintegrations per minute; FCS = fetal calf serum; IC 50  = median inhibitory concentration; IGF = insulin-like growth factor; IGFBP = IGF-binding protein; NP40 = Nonidet P40; OA = osteoarthritis; rhIGF-1 = recombinant human IGF-1; SEM = standard error; TBS = Tris-buffered saline.  ",
      "frame-id":"pass-PMC546277-UAZ-r1-546277",
      "section-id":"",
      "frame-type":"passage",
      "is-title":false,
      "section-name":"",
      "object-type":"frame",
      "index":"546277",
      "object-meta":{
        "component":"nxml2fries",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Pharmacological disruption of insulin like growth factor 1 binding to IGF binding proteins restores anabolic responses in human osteoarthritic chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-0",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":156,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":0,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Insulin like growth factor 1 ( IGF-1 ) has poor anabolic efficacy in cartilage in osteoarthritis ( OA ) , partly because of its sequestration by abnormally high levels of extracellular IGF binding proteins ( IGFBPs ) .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-1",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":370,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":160,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"We studied the effect of NBI-31772 , a small molecule that inhibits the binding of IGF-1 to IGFBPs , on the restoration of proteoglycan synthesis by human OA chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-2",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":540,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":371,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGFBPs secreted by human OA cartilage or cultured chondrocytes were analyzed by western ligand blot .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-3",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":641,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":541,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The ability of NBI-31772 to displace IGF-1 from IGFBPs was measured by radiobinding assay .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-4",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":732,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":642,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Anabolic responses in primary cultured chondrocytes were assessed by measuring the synthesis of proteoglycans in cetylpyridinium-chloride-precipitable fractions of cell associated and secreted  35 S labeled macromolecules .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-5",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":955,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":733,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The penetration of NBI-31772 into cartilage was measured by its ability to displace  125 I labeled IGF-1 from cartilage IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-6",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1083,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":956,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"We found that IGFBP-3 was the major IGFBP secreted by OA cartilage explants and cultured chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-7",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1186,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1084,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 inhibited the binding of  125 I labeled IGF-1 to IGFBP-3 at nanomolar concentrations .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-8",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1282,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1187,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"It antagonized the inhibitory effect of IGFBP-3 on IGF-1-dependent proteoglycan synthesis by rabbit chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-9",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1396,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1283,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The addition of NBI-31772 to human OA chondrocytes resulted in the restoration or potentiation of IGF-1-dependent proteoglycan synthesis , depending on the IGF-1 concentrations .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-10",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1573,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1397,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"However , NBI-31772 did not penetrate into cartilage explants .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-11",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1635,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1574,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This study shows that a new pharmacological approach that uses a small molecule inhibiting IGF-1 and IGFBP interaction could restore or potentiate proteoglycan synthesis in OA chondrocytes , thereby opening exciting possibilities for the treatment of OA and , potentially , of other joint related diseases .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-12",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1935,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1636,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Introduction .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-13",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1954,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1941,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Insulin like growth factor 1 ( IGF-1 ) was originally discovered in 1957 by Salmon and Daughaday as a potent growth-hormone-dependent serum factor able to stimulate sulfate incorporation by cartilage in vitro [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-14",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2175,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":1956,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"During postnatal , childhood , and pubertal life , IGF-1 stimulates the linear growth of bones by increasing the proliferation of epiphyseal chondrocytes and remodeling processes within the growth plate cartilage [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-15",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2408,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2176,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"During adulthood , IGF-1 plays a crucial role in the maintenance of homeostasis in articular cartilage , by stimulating the production of matrix proteins by chondrocytes [ XREF_BIBR-XREF_BIBR ] , counteracting their degradation [ XREF_BIBR-XREF_BIBR ] , and preventing cell death [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-16",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2703,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2409,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGF-1 displays its biological effects in cartilage through the IGF-1 tyrosine kinase receptor [ XREF_BIBR ] , structurally related to the heterotetrameric insulin receptor [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-17",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2885,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2704,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The accessibility of IGF-1 to its receptor is regulated by extracellular IGF binding proteins ( IGFBPs ) , secreted by chondrocytes but also by the other joint tissues .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-18",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3051,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":2886,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Although the secretion of IGFBPs by chondrocytes is constitutive , it is also stimulated by IGF-1 itself .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-19",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3156,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3052,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This mechanism regulates the amount of the free , bioactive form of IGF-1 [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-20",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3252,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3157,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In case of need , IGF-1 can be released from IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-21",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3304,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3253,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The proteolytic cleavage of IGFBPs by various proteases dramatically decreases their affinity for IGF-1 , thereby increasing its bioavailability [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-22",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3461,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3305,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The action of IGF-1 in cartilage is altered during ageing and in various pathologies such as osteoarthritis ( OA ) , leading to a decrease of anabolism and a detrimental increase in catabolic events [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-23",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3671,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3463,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Despite the increased degradation of cartilage in OA , the expression of IGF-1 mRNA is up-regulated in lesions of OA human cartilage [ XREF_BIBR-XREF_BIBR ] , and IGF-1 protein levels rise in the synovial fluid of OA patients compared to healthy subjects [ XREF_BIBR-XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-24",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3945,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3672,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In dogs , IGF-1 levels in a knee joint that had undergone cruciate ligament rupture were fourfold higher than in the contralateral , unaffected joint [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-25",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4106,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":3946,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This increased production of IGF-1 in OA reflected an attempt of cartilage to restore homeostasis , but it remained inefficacious .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-26",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4236,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4107,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGF-1 receptors were present and functional in chondrocytes from OA cartilage and thus were not responsible for the inability of IGF-1 to trigger anabolic events [ XREF_BIBR , XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-27",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4431,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4237,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGFBPs are key players in the failure of cartilage to readjust to homeostasis during OA .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-28",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4521,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4433,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Of the six known IGFBPs , IGFBP-2 , -3 , and -4 are known to be secreted by articular cartilage or chondrocytes [ XREF_BIBR-XREF_BIBR ] , with IGFBP-3 being the predominant one [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-29",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4705,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4522,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The expression of IGFBP-3 was 24 times as high in human OA chondrocytes as in normal chondrocytes [ XREF_BIBR ] , and the amount of IGFBP-3 synthesized by OA cartilage was three times that in normal cartilage [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-30",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4924,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4706,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Similarly , the amount of IGFBP-3 in OA was three times that seen in healthy cartilage , and was positively correlated with the severity of the disease [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-31",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5087,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":4925,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The molar concentration of IGFBP-3 in the synovial fluid of OA patients was higher than that of IGF-1 , leading to a molar ratio of free to bound IGF-1 of less than 1 [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-32",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5276,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5088,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In such conditions , no more IGF-1 should be able to reach its receptors on cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-33",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5362,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5277,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To demonstrate the involvement of IGFBPs in IGF-1 bioactivity in vitro , Sunic and co-workers showed that des ( 1-3 ) IGF-1 , a mutant of IGF-1 lacking the N-terminal tripeptide and with decreased affinity for IGFBPs , stimulated the production of proteoglycans by cultured chondrocytes to a higher extent than did IGF-1 [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-34",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5691,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5363,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Additionally , anabolic responses of chondrocytes to IGF-1 were dependent on the level of secreted IGFBPs , and the addition of IGFBP-3 blocked the effects of IGF-1 [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-35",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5867,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5692,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"According to the growing evidence that IGFBPs ( and especially IGFBP-3 ) are involved in the decline of the synthesizing responses of OA cartilage , we hypothesized that these proteins could be pharmacological targets for the treatment of OA .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-36",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6108,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":5869,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In this study , a nonpeptide small molecule previously described as a potent inhibitor of interaction between IGF and IGFBP [ XREF_BIBR ] was used as a potential tool to restore the anabolic response of OA chondrocytes to IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-37",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6334,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6109,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Results .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-38",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6346,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6338,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Implication of IGFBPs in the loss of anabolic response in OA human chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-39",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6430,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6350,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The ability of IGF-1 to stimulate proteoglycan synthesis in human OA chondrocytes was compared with that of R 3  IGF-1 , an IGF-1 analog with a greatly reduced affinity for IGFBPs                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-40",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6627,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6432,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"A 48-hour stimulation time with 2.7 nM IGF-1 was ineffective in promoting proteoglycan synthesis by chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-41",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6741,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6628,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"By contrast , 2.7 nM R 3  IGF-1 significantly stimulated total proteoglycan synthesis , by 45 % over that by unstimulated cells .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-42",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6867,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6742,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Since IGF-1 and R 3  IGF-1 have similar affinities for the IGF-1 receptor , the anabolic effect of IGF peptides depended on the presence of IGFBPs in the extracellular medium .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-43",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7042,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":6868,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Identification of IGFBPs secreted by human OA cartilage and chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-44",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7119,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7046,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To analyze IGFBPs secreted by chondrocytes , aliquots of the secretion medium of primary cultured chondrocytes or cartilage explants were subjected to SDS-PAGE followed by western ligand blotting                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-45",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7332,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7121,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The identity of secreted IGFBPs was determined by running rhIGFBP-1 , -2 , -3 , -4 , -5 , and -6 in neighbouring wells during electrophoresis .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-46",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7470,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7333,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Primary cultured chondrocytes secreted IGFBP-3 as the majority IGFBP form ( appearing as a characteristic doublet at 39-42 kDa ) , and IGFBP-4 was also identified in all specimens consistently , although more faintly .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-47",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7684,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7471,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGFBP-2 was also found in some specimens .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-48",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7726,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7685,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"By contrast , IGFBP-3 was the only IGFBP secreted by OA cartilage explants from various specimens .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-49",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7824,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7727,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Effect of NBI-31772 on proteoglycan synthesis by rabbit articular chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-50",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7907,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7828,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Since they respond normally to IGF-1 , primary cultured rabbit articular chondrocytes were chosen to study the effect of exogenous IGFBP-3 and NBI-31772 on IGF-1 stimulated proteoglycan synthesis                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-51",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8120,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":7909,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGF-1 ( 1.3 nM ) alone stimulated total proteoglycan synthesis by a factor of 3.2                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-52",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8217,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8121,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The addition of a fourfold molar excess of IGFBP-3 completely abolished the anabolic effect of IGF-1 , and a slight deleterious effect was even noticed , with proteoglycan synthesis being 18 % less than the control value .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-53",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8436,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8218,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Further addition of NBI-31772 antagonized the neutralizing effect of IGFBP-3 on the anabolic effect of IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-54",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8546,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8437,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 ( 1 muM ) increased proteoglycan synthesis over that measured in the presence of IGF-1 plus IGFBP-3 by 28 % ( P < 0.05 ) and this increase reached 210 % with 10 muM of NBI-31772 ( P < 0.001 ) , corresponding to 154 % over the basal control value .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-55",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8793,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8547,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 by itself had no effect on proteoglycan synthesis .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-56",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8854,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8794,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 at 10 muM significantly stimulated the percentage of cell associated proteoglycans in the presence of IGF-1 plus IGFBP-3 , with a value of 40.3 % compared to a control value of 31.3 % ( P < 0.001 )                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-57",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9074,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":8855,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 alone did not significantly affect the ratio of cell associated proteoglycans .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-58",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9163,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9075,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Effect of NBI-31772 on proteoglycan synthesis by human OA chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-59",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9238,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9167,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Depending on the concentration used , IGF-1 has no or little effect on proteoglycan synthesis by human OA chondrocytes , whereas R 3  IGF-1 displays higher activity .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-60",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9403,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9240,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"It therefore seems that endogenous IGFBPs are the main determinants of chondrocyte insensitivity to the action of IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-61",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9524,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9404,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To further test this hypothesis , we incubated chondrocytes for 24 hours with IGF-1 and then added NBI-31772 to the medium and incubated them for 24 more hours .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-62",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9684,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9525,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"We hypothesized that , once captured by IGFBPs secreted in the extracellular medium , IGF-1 should be released by addition of the small inhibitor compound and be able to interact again with its receptor .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-63",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9886,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9685,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"IGF-1 at 3.3 nM had no significant anabolic effect ( an increase of 7.8 % ; not statistically significant ) in comparison with the basal control , but the addition of NBI-31772 at 10 muM stimulated proteoglycan synthesis by 47 % over IGF-1 alone ( P < 0.001 ) , or 58 % over the basal control                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-64",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10187,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":9888,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"A stimulating concentration of IGF-1 ( 13.3 nM ) led to a 52.4 % increase in proteoglycan synthesis over the basal control , and further addition of NBI-31772 at 10 muM brought this increase to 104.2 % ( 34 % more than with IGF-1 alone ; P < 0.001 )                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-65",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10445,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10188,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 alone ( added to cells that did not receive IGF-1 ) had no effect on proteoglycan synthesis .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-66",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10546,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10446,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"These results suggest that NBI-31772 either restored or augmented IGF-1-dependent anabolism in human OA chondrocytes by disrupting the interaction of the growth factor with its endogenous IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-67",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10742,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10547,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"As also observed in rabbit articular chondrocytes , NBI-31772 at 10 muM stimulated the percentage of cell associated proteoglycans compared with IGF-1 used at 3.3 nM or 13.3 nM , with values significantly increasing from 13.5 % to 15.9 % of total proteoglycans in the former case ( P < 0.05 ) , and from 13.0 % to 16.0 % ( P < 0.001 ) in the latter case                             .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-68",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11115,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":10743,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In further experiments , the stimulating effect of NBI-31772 was tested in the presence of R 3  IGF-1 by comparison with IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-69",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11243,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11117,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Since R 3  IGF-1 does not bind to IGFBPs , we hypothesized that NBI-31772 should not affect proteoglycan synthesis induced by this mutant IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-70",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11387,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11244,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"As expected , NBI-31772 stimulated IGF-1-dependent proteoglycan synthesis in a dose dependent manner                , but R 3  IGF-1 activity , which by itself was highly enhanced compared with IGF-1 , remained unaffected by NBI-31772                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-71",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11636,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11388,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This experiment definitely ruled out the possibility that NBI-31772 may act independently of its ability to inhibit the interaction between IGF-1 and IGFBP .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-72",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11793,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11637,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"However , the percentage of cell associated proteoglycans was significantly increased from 13.6 % to 16.5 % ( P < 0.001 ) when 10 muM NBI-31772 was added to the medium containing R 3  IGF-1                , showing that the effect of NBI-31772 on proteoglycan redistribution depended on cell responses to IGF-1 peptides , rather than to their ability to bind to IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-73",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12157,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":11794,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 alone did not affect the percentage of cell associated proteoglycans ( not shown ) .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-74",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12249,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12158,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Effect of NBI-31772 on  125 I labeled IGF-1 binding to human OA chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-75",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12330,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12253,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To ensure that NBI-31772 did not affect the binding of IGF-1 to its receptors , it was used as a potential competitor in a cell binding assay on human OA chondrocytes                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-76",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12514,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12332,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"125 I labeled IGF-1 bound specifically to confluent chondrocytes , since 84 % of the radioactivity could be released by the addition of excess unlabeled IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-77",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12673,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12516,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"When added at the highest dose used in biological assays ( 10 muM ) , NBI-31772 did not displace specific  125 I labeled IGF-1 binding from the cell surface .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-78",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12828,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12674,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Competition assay of NBI-31772 with  125 I labeled IGF-1 for binding to cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-79",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12914,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12832,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This experiment was set up to determine whether NBI-31772 would displace  125 I labeled IGF-1 from its IGFBPs within cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-80",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13043,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":12916,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To ensure maximal homogeneity , 20 explants coming from a restricted area of a single cartilage specimen were selected for each well .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-81",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13176,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13044,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Cartilage explants previously incubated with potential competitors or not were further incubated with 20,000 dpm  125 I labeled IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-82",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13311,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13177,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The amount of  125 I labeled IGF-1 remaining in cartilage in the presence of 11.7 nM IGF-1 was 53 % of the control value , demonstrating that only 47 % of the radiolabeled peptide was bound specifically to proteins within cartilage                .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-83",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13557,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13312,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"No further displacement was observed with higher IGF-1 concentrations ( not shown ) .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-84",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13640,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13558,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"About 43 % of the cartilage associated radioactivity was removed with 1.5 M NaCl , showing that nearly half of the  125 I labeled IGF-1 was bound in a nonspecific manner to cartilage through ionic interactions , possibly to proteoglycans .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-85",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13876,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13641,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"By contrast with IGF-1 , R 3  IGF-1 did not compete with  125 I labeled IGF-1 , demonstrating that IGF-1 was primarily bound to IGFBPs within cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-86",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14027,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":13877,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 ( 10 muM ) did not compete with  125 I labeled IGF-1 binding to cartilage IGFBPs , suggesting that it did not penetrate into cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-87",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14170,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14028,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Discussion .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-88",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14185,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14174,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The loss of anabolic responses of chondrocytes to IGF-1 is one of the reasons why diseased cartilage can not counteract the action of catabolic cytokines during OA .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-89",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14350,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14187,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The results of the present study show that NBI-31772 , a small , nonpeptide compound that binds to endogenous IGFBPs and releases biologically active IGF-1 [ XREF_BIBR ] , can restore proteoglycan synthesis by human OA chondrocytes , therefore opening the possibility of a new field of pharmacological intervention for the treatment of OA and other joint related diseases .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-90",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14717,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14351,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"As previously demonstrated in ovine and bovine chondrocytes [ XREF_BIBR ] , a mutant of IGF-1 with strongly decreased affinity for IGFBPs was able to stimulate the synthesis of proteoglycans by OA chondrocytes to a higher extent than did IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-91",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14960,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14719,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This simple but convincing experiment was the basis for suspecting the involvement of endogenous IGFBPs in the loss of IGF-1 effects in OA chondrocytes , and it was a prerequisite to justify their targeting .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-92",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15167,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":14961,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Three forms of IGFBPs were found to be secreted by human OA chondrocytes , the major one being IGFBP-3 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-93",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15270,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15168,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"OA cartilage explants secreted IGFBP-3 exclusively .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-94",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15322,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15271,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In a functional radiobinding assay , NBI-31772 displaced the binding of  125 I labeled IGF-1 at a molar concentration 20 times that of unlabeled IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-95",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15473,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15323,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Although the ability of NBI-31772 to displace  125 I labeled IGF-1 from the other IGFBPs has not been checked in this study , it has been previously shown that it can interact with all six IGFBPs with similar efficacy [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-96",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15703,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15474,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Therefore , it is probable that in the experiments with OA chondrocytes , NBI-31772 also acted by displacing IGF-1 from IGFBP-2 and -4 in addition to IGFBP-3 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-97",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15860,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15704,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In the first set of experiments with rabbit chondrocytes , IGFBP-3 at a concentration four times that of IGF-1 completely abolished the stimulation of proteoglycan synthesis by IGF-1 , and NBI-31772 partially restored IGF-1-dependent synthetic activities at 1 muM and almost totally at 10 muM .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-98",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16153,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":15862,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"These concentrations were much higher than those found to displace  125 I labeled IGF-1 from IGFBP-3 in the radiobinding assay .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-99",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16281,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16154,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This discrepancy was also found in a previous study reporting the activity of NBI-31772 on the reversal of IGFBP-3 inhibition of Balb and c3T3 IGF-1-dependent proliferation [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-100",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16463,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16282,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The higher amounts of IGFBP-3 used in the biological assays compared with the radiobinding assay may in part account for this discrepancy .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-101",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16602,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16464,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"On the other hand , differences may rest on a decreased stability of the chemical compound in a biological environment and/or to its capture or neutralization by chondrocyte secreted proteins or macromolecules , thus limiting its activity .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-102",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16840,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16603,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Similar results were found for human OA chondrocytes , without addition of IGFBP-3 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-103",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16923,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16841,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In this cellular model , we asked whether NBI-31772 could displace IGF-1 from endogenous IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-104",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17019,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":16924,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"As also found by others [ XREF_BIBR , XREF_BIBR , XREF_BIBR ] , IGF-1 was either not detectable or poorly detectable in the extracellular medium , reflecting poor ability of chondrocytes to secrete IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-105",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17216,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17020,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Thus , it was given exogenously .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-106",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17248,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17217,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"The addition of NBI-31772 was able to activate or increase proteoglycan synthesis , showing that complexes of IGF-1 with IGFBP could be disrupted to release bioactive IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-107",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17421,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17249,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"NBI-31772 also significantly increased the ratio of cell associated proteoglycans in the presence of IGF-1 and IGFBP complexes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-108",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17545,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17422,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"When , in these experiments , IGF-1 was replaced by R 3  IGF-1 , the stimulating effect of NBI-31772 on proteoglycan synthesis was completely abolished , thus ruling out the possibility that NBI-31772 may act independently of the inhibition of IGF-1-binding to IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-109",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17810,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17546,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"However , an increase of cell associated proteoglycans was still observed , showing that this effect of NBI-31772 occurred apart from IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-110",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17950,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17811,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Although unexplained , this mechanism may be important in a pathological context , since communication between chondrocytes and the extracellular matrix is disrupted in OA , and an increase of pericellular proteoglycans may help to maintain chondrocytes in a more favorable environment .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-111",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18234,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":17951,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Under physiological conditions , IGF-1 and IGFBP complexes can be disrupted by various proteases [ XREF_BIBR ] , thereby releasing active IGF-1 .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-112",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18372,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18236,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In a recent report by Fowlkes and co-workers , matrix metalloproteinase 3 was able to disrupt IGF and IGFBP -3 complexes and to liberate free , intact IGFs able to phosphorylate the IGF-1 receptor and to trigger cell proliferation [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-113",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18609,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18373,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"A few different approaches have been used to prevent excessive sequestration of IGF-1 and restore its bioavailabity in pathological conditions .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-114",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18753,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18610,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Mutant peptides of IGF-1 still able to bind to IGFBPs but with very weak affinity for the IGF-1 receptor were designed to displace native IGF-1 from endogenous IGFBPs [ XREF_BIBR-XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-115",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18943,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18754,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Phage displayed peptide libraries yielded small peptide compounds able to selectively displace IGF-1 from IGFBP-1 or IGFBP-3 [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-116",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19091,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":18944,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"From the last generation , low-molecular-weight compounds ( fluorenylmethoxycarbonyl derivatives ) were shown to bind to the IGF-1 binding site on IGFBP-5 [ XREF_BIBR ] , and small isoquinoline compounds were shown to displace IGFs from IGFBPs without selectivity for a particular IGFBP [ XREF_BIBR , XREF_BIBR , XREF_BIBR , XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-117",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19425,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19092,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"These molecules have been proposed as potential drug candidates for the treatment of diabetes [ XREF_BIBR , XREF_BIBR ] , renal disease [ XREF_BIBR ] , or neurodegenerative diseases [ XREF_BIBR , XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-118",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19622,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19426,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Most of the current pharmacological approaches for the treatment of OA aim to prevent catabolism by blocking actors of the deleterious cascade , while restoration of anabolism or cartilage regeneration still rests on invasive procedures [ XREF_BIBR ] .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-119",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19872,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19624,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In this context , in situ cartilage regeneration by growth-factor therapy , including targeting of cartilage defects with fibrin-( chondrocyte )-IGF-1 composites [ XREF_BIBR , XREF_BIBR ] , or gene therapy with IGF-1 delivered intra-articularly [ XREF_BIBR-XREF_BIBR ] , have been proposed .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-120",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20151,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":19873,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"To be effective , the amount of IGF-1 delivered within the joint in this way should exceed the binding capacity of local IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-121",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20279,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20152,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In addition to noninvasive intervention , one of the main advantages of our proposed strategy would be to target directly the actors of cartilage unresponsiveness to IGF-1 , and to bypass the capture of exogenous IGF-1 by IGFBPs .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-122",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20507,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20280,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Keeping this objective in mind , it is clear that the small compound used in this study , NBI-31772 , should be considered only a tool to demonstrate the concept in vitro .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-123",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20676,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20508,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Indeed , concentrations of NBI-31772 active in the biological assays were relatively high ( 1-10 muM ) and would be incompatible with in vivo trials .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-124",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20823,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20677,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Secondly , NBI-31772 did not penetrate into cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-125",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20877,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20824,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This should not be an exclusion criterion per se , since one may hypothesize that if the compound were capable of reaching the synovial fluid or cartilage surrounding tissues , it might release IGF-1 captured by IGFBPs in these tissues and sustain its action in cartilage .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-126",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21148,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":20878,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"However , the in vivo duration of action of NBI-31772 was short [ XREF_BIBR ] , which implies that in vivo trials to assess the therapeutic relevance of this class of molecule in joint diseases need to be performed with more stable molecules .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-127",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21387,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21149,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In view of a therapeutic application , the optimization of small chemical inhibitors of IGF and IGFBP interaction would be preferred over the use of IGF-1 peptide mutants ( either binding receptors and triggering biological effects without binding IGFBPs , or , conversely , displacing endogenous IGF-1 from IGFBPs without binding receptors ) , since the former should be more easily optimizable while the latter should be more susceptible to the attack by proteases .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-128",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21844,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21388,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"In a clinical context , compounds that selectively target IGFBP-3 would be mandatory if oral availability is preferred , in order to avoid or to limit side effects caused by displacing IGF-1 from its binding proteins in undesirable tissues .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-129",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22083,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":21845,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This question of selectivity may not be so important in the case of topical delivery , and local treatment should be envisaged instead .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-130",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22218,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22084,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Conclusion .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-131",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22233,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22222,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"A small , nonpeptide pharmacological inhibitor of IGF and IGFBP interaction restored or enhanced the IGF-1-dependent proteoglycan synthesis by human osteoarthritic chondrocytes .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-132",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22407,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22235,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"This finding offers a rationale for pharmacological intervention in the treatment of cartilage repair in osteoarthritis and potentially of other joint related diseases and shows that IGFBPs are pertinent target candidates for this purpose .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-133",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22647,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22408,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Competing interests .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-134",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22671,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22651,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"None declared .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-135",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22687,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22673,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"Abbreviations .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-136",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22705,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22691,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    },
    {
      "text":"BSA = bovine serum albumin ; DPBS = Dulbecco 's phosphate buffered saline without calcium and magnesium ; dpm = disintegrations per minute ; FCS = fetal calf serum ; IC 50  = median inhibitory concentration ; IGF = insulin like growth factor ; IGFBP = IGF binding protein ; NP40 = Nonidet P40 ; OA = osteoarthritis ; rhIGF-1 = recombinant human IGF-1 ; SEM = standard error ; TBS = Tris buffered saline .",
      "frame-id":"sent-PMC546277-UAZ-r1-546277-137",
      "passage":"pass-PMC546277-UAZ-r1-546277",
      "frame-type":"sentence",
      "end-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":23098,
        "object-type":"relative-pos"
      },
      "object-type":"frame",
      "start-pos":{
        "reference":"pass-PMC546277-UAZ-r1-546277",
        "offset":22707,
        "object-type":"relative-pos"
      },
      "object-meta":{
        "component":"BioNLPProcessor",
        "object-type":"meta-info"
      }
    }
  ],
  "object-type":"frame-collection",
  "object-meta":{
    "processing-end":"2016-09-11T16:48:08Z",
    "doc-id":"PMC546277",
    "component-type":"machine",
    "component":"Reach",
    "processing-start":"2016-09-11T16:45:58Z",
    "object-type":"meta-info",
    "organization":"UAZ"
  }
}
